INTENSIFICATION DU TRAITEMENT CHELATEUR DU FER PAR LA DESFERRIOXAMINE A L'AIDE D'UNE CHAMBRE IMPLANTABLE D'ACCESS VEINEUX (PORT-A-CATH)

Translated title of the contribution: Intensifying iron chelating therapy with deferoxamine using implanted venous access catheters (Port-A-Cath)

M. De Montalembert, D. Jan, M. Clairicia, T. Hannedouche, D. Sidi, R. Girot

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis. It must be perfused daily, intravenously or subcutaneously, during several hours emplantable infusion devices (Port-A-Cath) offer intravenous access, allowing to use higher doses, while avoiding local swelling due to subcutaneous injections. This device was inserted in 7 major thalassemic patients who presented with severe complications of iron overload, including 4 of them with signs of cardiac failure. Ferritinemias of all patients were lowered after intensifying iron chelation: cardiac function improved drastically in 2 patients. Devices were responsible for some complications: occlusion in one patient, local infections in two. This way of administration of desferal seems useful in patients with high ferritinemia and/or organic complications related to hemochromatosis.

Original languageFrench
Pages (from-to)159-163
Number of pages5
JournalArchives Francaises de Pediatrie
Volume49
Issue number3
StatePublished - Jan 1 1992
Externally publishedYes

    Fingerprint

Keywords

  • Thalassemia
  • blood transfusion
  • child
  • deferoxamine
  • heart failure congestive
  • hemosiderosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this